Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Characterization of Mutational Tolerance of a Viral RNA-Protein Interaction.

Prostova MA, Smertina E, Bakhmutov DV, Gasparyan AA, Khitrina EV, Kolesnikova MS, Shishova AA, Gmyl AP, Agol VI.

Viruses. 2019 May 25;11(5). pii: E479. doi: 10.3390/v11050479.

2.

Emergency Services of Viral RNAs: Repair and Remodeling.

Agol VI, Gmyl AP.

Microbiol Mol Biol Rev. 2018 Mar 14;82(2). pii: e00067-17. doi: 10.1128/MMBR.00067-17. Print 2018 Jun. Review.

3.

Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications.

Korotkova E, Laassri M, Zagorodnyaya T, Petrovskaya S, Rodionova E, Cherkasova E, Gmyl A, Ivanova OE, Eremeeva TP, Lipskaya GY, Agol VI, Chumakov K.

Viruses. 2017 Nov 22;9(11). pii: E353. doi: 10.3390/v9110353.

4.

A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.

Korotkova EA, Gmyl AP, Yakovenko ML, Ivanova OE, Eremeeva TP, Kozlovskaya LI, Shakaryan AK, Lipskaya GY, Parshina IL, Loginovskikh NV, Morozova NS, Agol VI.

J Virol. 2016 Jun 10;90(13):5978-88. doi: 10.1128/JVI.00277-16. Print 2016 Jul 1.

5.

Mutational robustness and resilience of a replicative cis-element of RNA virus: Promiscuity, limitations, relevance.

Prostova MA, Gmyl AP, Bakhmutov DV, Shishova AA, Khitrina EV, Kolesnikova MS, Serebryakova MV, Isaeva OV, Agol VI.

RNA Biol. 2015;12(12):1338-54. doi: 10.1080/15476286.2015.1100794.

6.

The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt.

Yakovenko ML, Gmyl AP, Ivanova OE, Eremeeva TP, Ivanov AP, Prostova MA, Baykova OY, Isaeva OV, Lipskaya GY, Shakaryan AK, Kew OM, Deshpande JM, Agol VI.

Euro Surveill. 2014 Feb 20;19(7):20706.

7.

Cytopathic effects: virus-modulated manifestations of innate immunity?

Agol VI.

Trends Microbiol. 2012 Dec;20(12):570-6. doi: 10.1016/j.tim.2012.09.003. Epub 2012 Oct 13. Review.

PMID:
23072900
8.

Suppression of injuries caused by a lytic RNA virus (mengovirus) and their uncoupling from viral reproduction by mutual cell/virus disarmament.

Mikitas OV, Ivin YY, Golyshev SA, Povarova NV, Galkina SI, Pletjushkina OY, Nadezhdina ES, Gmyl AP, Agol VI.

J Virol. 2012 May;86(10):5574-83. doi: 10.1128/JVI.07214-11. Epub 2012 Mar 21.

9.

Viral security proteins: counteracting host defences.

Agol VI, Gmyl AP.

Nat Rev Microbiol. 2010 Dec;8(12):867-78. doi: 10.1038/nrmicro2452. Epub 2010 Nov 9. Review.

PMID:
21060318
10.

Theiler's murine encephalomyelitis virus L* amino acid position 93 is important for virus persistence and virus-induced demyelination.

Stavrou S, Baida G, Viktorova E, Ghadge G, Agol VI, Roos RP.

J Virol. 2010 Feb;84(3):1348-54. doi: 10.1128/JVI.01585-09. Epub 2009 Nov 18.

11.

Interactions between viral and prokaryotic pathogens in a mixed infection with cardiovirus and mycoplasma.

Lidsky PV, Romanova LI, Kolesnikova MS, Bardina MV, Khitrina EV, Hato SV, van Kuppeveld FJ, Agol VI.

J Virol. 2009 Oct;83(19):9940-51. doi: 10.1128/JVI.01167-09. Epub 2009 Jul 15.

12.

Antiapoptotic activity of the cardiovirus leader protein, a viral "security" protein.

Romanova LI, Lidsky PV, Kolesnikova MS, Fominykh KV, Gmyl AP, Sheval EV, Hato SV, van Kuppeveld FJ, Agol VI.

J Virol. 2009 Jul;83(14):7273-84. doi: 10.1128/JVI.00467-09. Epub 2009 May 6.

13.

Mengovirus-induced rearrangement of the nuclear pore complex: hijacking cellular phosphorylation machinery.

Bardina MV, Lidsky PV, Sheval EV, Fominykh KV, van Kuppeveld FJ, Polyakov VY, Agol VI.

J Virol. 2009 Apr;83(7):3150-61. doi: 10.1128/JVI.01456-08. Epub 2009 Jan 14.

14.

Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance.

Yakovenko ML, Korotkova EA, Ivanova OE, Eremeeva TP, Samoilovich E, Uhova I, Gavrilin GV, Agol VI.

J Virol. 2009 Apr;83(7):3402-6. doi: 10.1128/JVI.02122-08. Epub 2009 Jan 7.

15.

Immunisation against poliomyelitis: moving forward.

Ehrenfeld E, Glass RI, Agol VI, Chumakov K, Dowdle W, John TJ, Katz SL, Miller M, Breman JG, Modlin J, Wright P.

Lancet. 2008 Apr 19;371(9621):1385-7. doi: 10.1016/S0140-6736(08)60597-8. No abstract available.

PMID:
18424327
16.

Vaccination against polio should not be stopped.

Chumakov K, Ehrenfeld E, Wimmer E, Agol VI.

Nat Rev Microbiol. 2007 Dec;5(12):952-8. Review.

PMID:
17965726
17.

Significance of the C-terminal amino acid residue in mengovirus RNA-dependent RNA polymerase.

Dmitrieva TM, Alexeevski AV, Shatskaya GS, Tolskaya EA, Gmyl AP, Khitrina EV, Agol VI.

Virology. 2007 Aug 15;365(1):79-91. Epub 2007 Apr 27.

18.

A GCUA tetranucleotide loop found in the poliovirus oriL by in vivo SELEX (un)expectedly forms a YNMG-like structure: Extending the YNMG family with GYYA.

Melchers WJ, Zoll J, Tessari M, Bakhmutov DV, Gmyl AP, Agol VI, Heus HA.

RNA. 2006 Sep;12(9):1671-82. Epub 2006 Aug 7.

19.

Polyadenylation of genomic RNA and initiation of antigenomic RNA in a positive-strand RNA virus are controlled by the same cis-element.

van Ooij MJ, Polacek C, Glaudemans DH, Kuijpers J, van Kuppeveld FJ, Andino R, Agol VI, Melchers WJ.

Nucleic Acids Res. 2006 May 31;34(10):2953-65. Print 2006.

20.

Vaccine-derived polioviruses.

Agol VI.

Biologicals. 2006 Jun;34(2):103-8. Epub 2006 May 2.

PMID:
16650771
21.

Molecular mechanisms of poliovirus variation and evolution.

Agol VI.

Curr Top Microbiol Immunol. 2006;299:211-59. Review.

PMID:
16568901
22.

[How the poliovirus changes a cell].

Lidskiĭ PV, Agol VI.

Vopr Virusol. 2006 Jan-Feb;51(1):4-11. Review. Russian.

PMID:
16515034
23.

Nucleocytoplasmic traffic disorder induced by cardioviruses.

Lidsky PV, Hato S, Bardina MV, Aminev AG, Palmenberg AC, Sheval EV, Polyakov VY, van Kuppeveld FJ, Agol VI.

J Virol. 2006 Mar;80(6):2705-17.

24.

Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties.

Yakovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP, Eremeeva TP, Baykova OY, Chumakov KM, Agol VI.

J Virol. 2006 Mar;80(6):2641-53.

25.

[Variable mechanisms of RNA-recombination].

Gmyl' AP, Agol VI.

Mol Biol (Mosk). 2005 Jul-Aug;39(4):618-32. Review. Russian.

PMID:
16083010
26.

Don't drop current vaccine until we have new ones.

Agol VI, Chumakov K, Ehrenfeld E, Wimmer E.

Nature. 2005 Jun 16;435(7044):881. No abstract available.

PMID:
15959489
27.

Variability in apoptotic response to poliovirus infection.

Romanova LI, Belov GA, Lidsky PV, Tolskaya EA, Kolesnikova MS, Evstafieva AG, Vartapetian AB, Egger D, Bienz K, Agol VI.

Virology. 2005 Jan 20;331(2):292-306.

28.

Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, Eremeeva TP, Krasnoproshina LI, Romanenkova NI, Rozaeva NR, Sirota L, Agol VI, Chumakov KM.

J Virol. 2005 Jan;79(2):1062-70.

29.

Bidirectional increase in permeability of nuclear envelope upon poliovirus infection and accompanying alterations of nuclear pores.

Belov GA, Lidsky PV, Mikitas OV, Egger D, Lukyanov KA, Bienz K, Agol VI.

J Virol. 2004 Sep;78(18):10166-77.

30.

Circulating vaccine-derived polioviruses: current state of knowledge.

Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA.

Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26. Review.

31.

Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, Kew OM, Agol VI.

J Virol. 2003 Dec;77(23):12460-5.

32.

Nonreplicative homologous RNA recombination: promiscuous joining of RNA pieces?

Gmyl AP, Korshenko SA, Belousov EV, Khitrina EV, Agol VI.

RNA. 2003 Oct;9(10):1221-31.

33.

Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses.

Cherkasova E, Laassri M, Chizhikov V, Korotkova E, Dragunsky E, Agol VI, Chumakov K.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9398-403. Epub 2003 Jul 23.

34.

Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha.

Evstafieva AG, Belov GA, Rubtsov YP, Kalkum M, Joseph B, Chichkova NV, Sukhacheva EA, Bogdanov AA, Pettersson RF, Agol VI, Vartapetian AB.

Exp Cell Res. 2003 Apr 1;284(2):211-23.

PMID:
12651154
35.

The major apoptotic pathway activated and suppressed by poliovirus.

Belov GA, Romanova LI, Tolskaya EA, Kolesnikova MS, Lazebnik YA, Agol VI.

J Virol. 2003 Jan;77(1):45-56.

36.

[Viral infectious and cell differentiation].

Agol VI.

Ontogenez. 2002 Sep-Oct;33(5):343-8. Review. Russian.

PMID:
12391915
37.

Unstable receptors disappear from cell surface during poliovirus infection.

Neznanov N, Chumakov KP, Ullrich A, Agol VI, Gudkov AV.

Med Sci Monit. 2002 Oct;8(10):BR391-6.

PMID:
12388911
38.

Long-term circulation of vaccine-derived poliovirus that causes paralytic disease.

Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI.

J Virol. 2002 Jul;76(13):6791-9.

39.

[Genomic instability in picornaviruses].

Agol VI.

Mol Biol (Mosk). 2002 Mar-Apr;36(2):286-95. Review. Russian.

PMID:
11969090
40.

Some problems of molecular biology of poliovirus infection relevant to pathogenesis, viral spread and evolution.

Agol VI, Belov GA, Cherkasova EA, Gavrilin GV, Kolesnikova MS, Romanova LI, Tolskaya EA.

Dev Biol (Basel). 2001;105:43-50. Review.

PMID:
11763336
41.

Cell-specific proteins regulate viral RNA translation and virus-induced disease.

Pilipenko EV, Viktorova EG, Guest ST, Agol VI, Roos RP.

EMBO J. 2001 Dec 3;20(23):6899-908.

42.

New ways of initiating translation in eukaryotes.

Schneider R, Agol VI, Andino R, Bayard F, Cavener DR, Chappell SA, Chen JJ, Darlix JL, Dasgupta A, Donzé O, Duncan R, Elroy-Stein O, Farabaugh PJ, Filipowicz W, Gale M Jr, Gehrke L, Goldman E, Groner Y, Harford JB, Hatzglou M, He B, Hellen CU, Hentze MW, Hershey J, Hershey P, Hohn T, Holcik M, Hunter CP, Igarashi K, Jackson R, Jagus R, Jefferson LS, Joshi B, Kaempfer R, Katze M, Kaufman RJ, Kiledjian M, Kimball SR, Kimchi A, Kirkegaard K, Koromilas AE, Krug RM, Kruys V, Lamphear BJ, Lemon S, Lloyd RE, Maquat LE, Martinez-Salas E, Mathews MB, Mauro VP, Miyamoto S, Mohr I, Morris DR, Moss EG, Nakashima N, Palmenberg A, Parkin NT, Pe'ery T, Pelletier J, Peltz S, Pestova TV, Pilipenko EV, Prats AC, Racaniello V, Read GS, Rhoads RE, Richter JD, Rivera-Pomar R, Rouault T, Sachs A, Sarnow P, Scheper GC, Schiff L, Schoenberg DR, Semler BL, Siddiqui A, Skern T, Sonenberg N, Sossin W, Standart N, Tahara SM, Thomas AA, Toulmé JJ, Wilusz J, Wimmer E, Witherell G, Wormington M.

Mol Cell Biol. 2001 Dec;21(23):8238-46. No abstract available.

43.

Poliovirus protein 3A inhibits tumor necrosis factor (TNF)-induced apoptosis by eliminating the TNF receptor from the cell surface.

Neznanov N, Kondratova A, Chumakov KM, Angres B, Zhumabayeva B, Agol VI, Gudkov AV.

J Virol. 2001 Nov;75(21):10409-20.

44.

[Translational control of the picornavirus phenotype].

Agol VI.

Mol Biol (Mosk). 2001 Jul-Aug;35(4):691-701. Review. Russian.

PMID:
11524956
45.

Molecular mechanisms of translation initiation in eukaryotes.

Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, Hellen CU.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7029-36. Review.

46.

Early alteration of nucleocytoplasmic traffic induced by some RNA viruses.

Belov GA, Evstafieva AG, Rubtsov YP, Mikitas OV, Vartapetian AB, Agol VI.

Virology. 2000 Sep 30;275(2):244-8.

47.

A cell cycle-dependent protein serves as a template-specific translation initiation factor.

Pilipenko EV, Pestova TV, Kolupaeva VG, Khitrina EV, Poperechnaya AN, Agol VI, Hellen CU.

Genes Dev. 2000 Aug 15;14(16):2028-45.

48.

Cross-talk between orientation-dependent recognition determinants of a complex control RNA element, the enterovirus oriR.

Melchers WJ, Bakkers JM, Bruins Slot HJ, Galama JM, Agol VI, Pilipenko EV.

RNA. 2000 Jul;6(7):976-87.

49.

Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI.

J Virol. 2000 Aug;74(16):7381-90.

50.

Competing death programs in poliovirus-infected cells: commitment switch in the middle of the infectious cycle.

Agol VI, Belov GA, Bienz K, Egger D, Kolesnikova MS, Romanova LI, Sladkova LV, Tolskaya EA.

J Virol. 2000 Jun;74(12):5534-41.

Supplemental Content

Support Center